Clinical Trials

Cardiovascular (CV) diseases are the leading cause of morbidity and mortality throughout the world. In the last decades, considerable attention is given to the prevention of CV diseases, and also to modification of risk factors. Modifiable risk factors can be changed, such as diet, body weight, physical activity, blood pressure and diabetes, while genetics, age and gender represent non-modifiable risk factors.

Different epidemiological studies have pointed to the Asian population, especially the people of Japan, having surprisingly lower CV mortality and lower risk of coronary artery disease compared to the rest of the world population. Possible explanation of their longevity and lower CV risk may be the food they regularly consume. Besides the lower content of saturated fatty acids and frequent consumption of fish in their diet, it is possible that the consumption of soybeans contributes to lower CV morbidity and mortality in Japan. This also refers to nattō, traditional Japanese breakfast made from fermented soybeans.

In 1987 one interesting enzyme was isolated from nattō, and named nattokinase. It was observed that this enzyme has multiple beneficial effects that can be used in CV prevention and therapy. Most important effects were fibrinolytic and anti-thrombotic, followed by antihypertensive and neuroprotective effect of this powerful and natural enzyme.

Fibrinolytic Effect

Nattokinase dissolves fibrin, a protein important for stabilization of blood clots. Oral administration of nattokinase in experimentally induced thrombosis led to the degradation of blood clots, with restoration of normal blood flow after only five hours. Afterwards, it was observed that in experimentally induced pulmonary thrombosis in mice, nattokinase stopped the thrombotic proccess by mechanism similar to the mechanism of aspirin. Animal model of carotid thrombosis showed better fibrinolytic effect of nattokinase compared to plasmin. Administration of nattokinase restored 62% of initial blood flow in coronary artery, compared to 15.2% with plasmin administration. Additionally, nattokinase confirmed to be four times potent than plasmin in thrombus dissolution.

Clinical trials confirmed fibrinolytic effect of nattokinase. Oral administration of nattokinase in humans showed gradual increase in plasma fibrinolytic activity. Maximum concentration of nattokinase in blood was observed after 13 hours of oral administration of just one dose of nattokinase. Subsequent trials showed that after two months of oral administration of nattokinase, plasma levels of fibrinogen, coagulation factor VII, and factor VIII were significantly reduced. Decrease in these hematologic parameters was noted in healthy people, in people with elevated CV risk, and also in patients on dialysis.

Oral administration of only one dose of nattokinase is sufficient for fibrinolytic effect. This was observed in clinical study that enrolled 12 healthy people who took only one capsule of nattokinase (2000 FU) or capsule containing placebo. Significant increase in antithrombin blood concentration was noted only two hours after taking nattokinase. After four hours of nattokinase administration there was increase in concentration of fibrin degradation products, while after six hours there was increase in D-dimer concentration. Additionally, four hours after oral administration of nattokinase decrease in coagulation factor VIII activity was recorded, which pointed to different fibrinolytic mechanisms of this enzyme. Although the changes of these parameters were significant, they were still in the reference range.

Antihypertensive Effect

In 2008 first randomized trial analyzing the effects of nattokinase on arterial blood pressure in humans was published. This trial enrolled 86 subjects with prehypertension or stadium I hypertension, who received nattokinase (2000 FU once daily) or placebo per os, for eight weeks.

Nattokinase reduced systolic blood pressure for mean -5.55 mmHg more than placebo, as well as diastolic blood pressure (mean difference -2.84 mmHg).

Another similarly designed study explored the antihypertensive effect of nattokinase in patients with elevated arterial blood pressure, but for the first time in non-Asian population. This study included patients from USA and Canada, who’s dietary and lifestyle habits significantly differ from the Asian population. After eight weeks of oral administration of nattokinase, there was decrease in systolic blood pressure from mean 144± 1.5 mmHg to 140 ± 2.1 mmHg. However, observed reduction in systolic blood pressure showed no significant difference between patients taking nattokinase vs. placebo-group. However, decrease in diastolic blood pressure was significantly higher in patients taking nattokinase compared to patients in placebo-group, but affecting only male gender (from initial 86 mmHg to 81 ± 2.5 mmHg after eight weeks). Patients taking placebo had constant diastolic blood pressure throughout the study period (mean 88 ± 2.6 mmHg). Different results could be explained by the different study population included. Namely, non-Asian subjects had no prior contact with nattokinase, nor they have consumed nattō. It is possible that longer administration of nattokinase is necessary for antihypertensive effect to be registered.

Antihypertensive effect can partially be explained by the inhibition of angiotensin-converting enzyme (ACE). Such mechanism was observed on animal models with administered nattokinase.

Anti-Atherosclerotic Effect

Experimental studies, followed by clinical trials in humans, showed that nattokinase reduced the intima-media thickness in carotid artery, along with the reduction in atherosclerotic plaque size. Underlying mechanism of the anti-atherosclerotic effect may be the synergistic fibrinolytic, antithrombotic, and anticoagulant effect of this enzyme. Additionally, nattokinase administration was associated with larger plaque reduction compared to subjects taking simvastatin.

Although experimental studies showed that nattokinase is associated with significant reduction in total cholesterol, LDL-cholesterol and triglycerids, clinical testing in humans pointed to reduction in these parameters, which was statistically non-significant. It is possible that higher doses of nattokinase are required for its hypolipemic effect.

Anti-Platelet Effect

Nattokinase inhibits platelet aggregation in vitro and in vivo, with mechanism similar to the mechanism of aspirin. Namely, nattokinase inhibits thromboxane B2 production by the activated platelets, which results in decrease in platelet aggregation and antithrombotic effect. It was also observed that nattokinase might reduce aggregation of red blood cells, and therefore improve rheological characteristics of blood.

Neuroprotective Effect

Experimental studies showed that nattokinase is capable of degrading amyloid fibrils. Further research on neuroprotective effect of nattokinase was initiated, focusing on amyloid-related diseases, such as Alzheimer disease. Potential neuroprotective effect might be explained by the proteolytic, anti-inflammatory, and anti-apoptotic activity of nattokinase.

Neuroprotective effect was also registered in the experimental model of acute ischemic stroke. Observed decrease in infarction volume may be interpreted by the effect of nattokinase on vascular smooth muscle cells (myorelaxation and vasodilatation), and also by endothelial protection (via enhanced fibrinolysis and stimulation of endogenous thrombolysis).


  1. Ahmed HH, Nevein NF, Karima A, Hamza AH. Miracle enzymes serrapeptase and nattokinase mitigate neuroinflammation and apoptosis associated with Alzheimer’s disease in experimental model. WJPPS 2013;3:876–891.
  2. Fu Y-S, Li Y-L, Zhang Y. Toxicological safety assessment on safety of nattokinase capsule. PracPrev Med 2012;19:1714–1716.
  3. Ero MP, Ng CM, Mihailovski T, Harvey NR, Lewis BH. A pliot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med 2013;19(3):16-9.
  4. Fadl NN, Ahmed HH, Booles HF, Sayed AH. Serrapeptase and nattokinase intervention for relieveing Alzheimer’s disease pathophysiology in rat model. Hum Exp Toxicol 2013;32(7):721-35.
  5. Fujita M, Hong K, Ito Y, Fujii R, Kariya K, Nishimuro S. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull 1995;18:1387-91.
  6. Fujita M, Hong K, Nishimuro Characterization of nattokinase-degraded products from human fibrinogen or cross-linked fibrin. Fibrinolysis 1995;9(3):157-64.
  7. Hsia C-H, Shen M-C, Lin J-S, et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res 2009;29:190-6.
  8. su R-L, Lee K-T, Wang J-H, Lee LY, Chen RP. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. J Agric Food Chem 2008;57:503–508.
  9. Jang JY, Kim TS, Cai J, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Lab Anim Res 2013;29:221-5.
  10. Jensen G, Lenninger M, Ero M, Benson K. Consumtion od nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Interg Blood Press Control 2016;9:95-104.
  11. Ji H, Yu L, Liu K, et al. Mechanisms of nattokinase in protection of cerebral ischemia. Eur J Pharmacol 2014;745:144–151.
  12. Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res 2008;31:1583-8.
  13. Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep 2015;5:11601.
  14. Lampe BJ, English JC. Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food ChemToxicol 2016;88:87–99.
  15. Meng F, Xue F, Shi H. Effects of nattokinase on blood lipid and blood rheology in atherosclerosis model rat. Chin J Lab Diagn 2013;17:1567–1569.
  16. Metkar SK, Girigoswami A, Murugesan R, Girigoswami K. In vitro and in vivo insulin amyloid degradation mediated by Serratiopeptidase. Mater Sci Eng C Mater Biol Appl 2017;70:728–735.
  17. Milner M, Makse K. Natto and its active ingredient nattokinase – a potent and safe thrombolytic agent. Alternative & Complementary Therapies 2002;8(3):157-164.
  1. Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct 2012;3:674-8.
  2. Nagata C, Wada K, Tamura T, et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: theTakayama study. Am J Clin Nutr 2017;105:426–31.
  3. Pais E, Alexy T, Holsworth J, Ralph E, Meiselman HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006;35:139–142.
  4. Park KJ, Kang JI, Kim TS, Yeo IH. The antithrombotic and fibrinolytic effect of natto in hypercholesterolemia rats. Prev Nutr Food Sci 2012;17:78–82.
  5. Ren N, Chen H, Li Y, McGowan E, Lin Y. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Nat Med J China 2017;97:2038–2042.
  6. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinases. Acta Haematol 1990;84:139-43.
  7. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 1987;43:1110-1.
  8. Suzuki Y, Kondo K, Matsumoto Y, et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci 2003;73:1289-98.
  9. Suzuki Y, Kondo K, Ichise H, Tsukamoto Y, Urano T, Umemura K. Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition 2003;19:261–264.
  10. Wang J-M, Chen H-Y, Cheng S-M, Chen S-H, Yang L-L, Cheng F-C. Nattokinase reduces brain infarction, fibrinogen and activated partial thromboplastin time against cerebral ischemia-reperfusion injury. J Food Drug Anal 2012;3:686–691.
  11. Weng Y, Yao J, Sparks S, Wang KY. Nattokinase: an oral antithrombotic agent fot the prevention of cardiovascular disease. Int J Mol Sci 2017;18(3):523.
  12. Wu D-J, Lin C-S, Lee M-Y. Lipid-lowering effect of nattokinase in patients with primary hypercholesterolemia. Acta Cardiologica Sinica 2009;25:26–30.
  13. Xie S, Yu Z, Liu X. Preparation of nattokinase and study on its hypolipidemic effect. Chin J Biochem Pharm 2015;35:17–20.
  14. Xu J, Du M, Yang X, Chen Q, Chen H, Lin DH. Thrombolytic effects in vivo of nattokinase in a carrageenan-induced rat model of thrombosis. Acta Haematol 2014;132(2):247-53.
  15. Yang M, Mei Y, Liang Y. Effect of nattokinase extraction on anti-thrombosis function. Food Sci Technol 2013;38:197–200.